Novo Nordisk's Rybelsus hasn't lived up to expectations, say analysts

The Danish drugmaker’s diabetes pill hasn’t reached the success that was predicted three years ago, to the disappointment of analysts.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
by marketwire, translated by daniel pedersen

Novo Nordisk’s Rybelsus, a diabetes pill, is far from becoming the huge sales success it was heralded as prior to launching ­ a realization that is now disappointing analysts, reports Danish financial media Finans.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading